Stock Price
110.50
Daily Change
3.64 3.41%
Monthly
18.16%
Yearly
-61.06%
Q2 Forecast
101.70



Peers Price Chg Day Year Date
Avita Medical 1.10 -0.01 -0.90% -34.43% Jun/17
Ansell 29.40 0.14 0.46% -3.75% Jun/17
Cochlear 110.50 3.64 3.41% -61.06% Jun/17
CSL 106.87 0.62 0.58% -55.83% Jun/17
Fisher Paykel Healthcare 38.87 0.27 0.70% 5.48% Jun/17
Healius 0.39 0.002 0.51% -49.42% Jun/17
Integral Diagnostics 2.06 -0.02 -0.72% -9.87% Jun/17
Mesoblast 1.96 0.01 0.51% 9.50% Jun/17
Monash IVF 0.70 0.01 0.72% 11.20% Jun/17
Mayne Pharma 2.32 -0.03 -1.28% -56.55% Jun/17

Indexes Price Day Year Date
ASX200 8934 16.20 0.18% 4.72% Jun/17
ASX All Share 9183 51.40 0.56% 4.85% Jun/17
AU50 8723 37.90 0.44% 4.48% Jun/17

Cochlear traded at 109.05 this Wednesday June 17th, increasing 2.19 or 2.05 percent since the previous trading session. Looking back, over the last four weeks, Cochlear gained 16.61 percent. Over the last 12 months, its price fell by 61.57 percent. Looking ahead, we forecast Cochlear to be priced at 101.70 by the end of this quarter and at 95.77 in one year, according to Trading Economics global macro models projections and analysts expectations.

Cochlear Limited is an Australian-based company, which provides implantable hearing solutions. The Company designs and offers products and accessories for adults or children. The Company operates through three geographical segments: Americas, EMEA and Asia Pacific. Its products offer various ways to hear, such as automatically adjusting hearing to different environments and streaming sound from a smartphone. It provides various products, including Nucleus sound processors, Smart bimodal hearing solution, Nucleus implants, Nucleus implant reliability, Baha sound processors, Baha implants, Baha Softband, SoundArc. The Company’s accessories include True Wireless devices, Nucleus water-safe accessories, Keeping device in place.